SI3135691T1 - Anti-cmet antibody - Google Patents

Anti-cmet antibody

Info

Publication number: SI3135691T1
Authority: SI; Slovenia
Prior art keywords: cmet antibody; cmet; antibody
Prior art date: 2008-12-02

Application number

SI200931893T

Other languages

Slovenian (sl)

Inventor

Liliane Goetsch

Thierry Wurch

Cedric Bes

Original Assignee

Pierre Fabre Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-02

Filing date

2009-12-02

Publication date

2018-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3135691(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-02 Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en

2009-12-02 Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament

2018-12-31 Publication of SI3135691T1 publication Critical patent/SI3135691T1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)

SI200931893T 2008-12-02 2009-12-02 Anti-cmet antibody SI3135691T1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/IB2008/055663 WO2010064089A1 (en)	2008-12-02	2008-12-02	Novel anti-cmet antibody
US18450209P	2009-06-05	2009-06-05
EP16192250.5A EP3135691B1 (en)	2008-12-02	2009-12-02	Anti-cmet antibody

Publications (1)

Publication Number	Publication Date
SI3135691T1 true SI3135691T1 (en)	2018-12-31

Family

ID=41693124

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI200931680T SI2370468T1 (en)	2008-12-02	2009-12-02	ANTI-cMET ANTIBODY
SI200932092T SI3431502T1 (en)	2008-12-02	2009-12-02	Anti-cmet antibody
SI200931893T SI3135691T1 (en)	2008-12-02	2009-12-02	Anti-cmet antibody

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SI200931680T SI2370468T1 (en)	2008-12-02	2009-12-02	ANTI-cMET ANTIBODY
SI200932092T SI3431502T1 (en)	2008-12-02	2009-12-02	Anti-cmet antibody

Country Status (38)

Country	Link
US (4)	US8741290B2 (en)
EP (4)	EP3431502B1 (en)
JP (3)	JP5863458B2 (en)
KR (1)	KR101838299B1 (en)
CN (2)	CN102227446B (en)
AR (1)	AR074439A1 (en)
AU (3)	AU2009328318C1 (en)
BR (2)	BR122019023930B1 (en)
CA (1)	CA2743433C (en)
CL (2)	CL2011001296A1 (en)
CO (1)	CO6382139A2 (en)
CR (1)	CR20110324A (en)
CY (2)	CY1119172T1 (en)
DK (2)	DK3135691T3 (en)
EC (1)	ECSP11011127A (en)
ES (3)	ES2697098T3 (en)
GE (2)	GEP20135930B (en)
HR (2)	HRP20171011T8 (en)
HU (3)	HUE051288T2 (en)
IL (2)	IL213273A0 (en)
LT (2)	LT2370468T (en)
MA (1)	MA32892B1 (en)
MX (2)	MX2011005677A (en)
MY (2)	MY185200A (en)
NZ (1)	NZ593853A (en)
PE (1)	PE20120343A1 (en)
PH (1)	PH12015501515A1 (en)
PL (3)	PL3135691T3 (en)
PT (3)	PT3135691T (en)
RS (2)	RS56204B1 (en)
RU (2)	RU2015127471A (en)
SA (2)	SA112331005B1 (en)
SG (2)	SG187518A1 (en)
SI (3)	SI2370468T1 (en)
TN (1)	TN2011000216A1 (en)
TW (2)	TWI459964B (en)
WO (1)	WO2010069765A1 (en)
ZA (1)	ZA201105164B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2014681A1 (en)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) *	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
EP2287197A1 (en) *	2009-08-21	2011-02-23	Pierre Fabre Medicament	Anti-cMET antibody and its use for the detection and the diagnosis of cancer
ES2993335T3 (en)	2010-03-10	2024-12-27	Genmab As	Monoclonal antibodies against c-met
RU2013114783A (en)	2010-09-03	2014-10-10	Академиа Синика	ANTI-C-MET ANTIBODIES AND WAYS OF THEIR APPLICATION
BR122014027420A2 (en)	2010-11-03	2019-08-20	Argenx Bvba	ANTI C-MET ANTIBODIES
WO2012158818A2 (en)	2011-05-16	2012-11-22	Fabion Pharmaceuticals, Inc.	Multi-specific fab fusion proteins and methods of use
KR101865223B1 (en)	2011-10-05	2018-06-08	삼성전자주식회사	Anti c-Met humanized antibody and uses thereof
KR20130036993A (en) *	2011-10-05	2013-04-15	삼성전자주식회사	Antibodies specifically binding to epitope in sema domain of c-met
US9926364B2 (en)	2011-11-03	2018-03-27	Argen-X N.V.	Chimeric human-llama antigens and methods of use
KR101463098B1 (en) *	2011-11-28	2014-11-27	한국생명공학연구원	Cytotoxic drug conjugated c-Met-targeting full agonist human antibody and use thereof
US8900582B2 (en)	2011-12-22	2014-12-02	Samsung Electronics Co., Ltd.	Deimmunized anti c-Met humanized antibodies and uses thereof
EP2863946A4 (en)	2012-06-21	2016-04-13	Sorrento Therapeutics Inc	Antigen binding proteins that bind c-met
EP2708556B1 (en)	2012-09-12	2018-11-07	Samsung Electronics Co., Ltd	Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
KR101645905B1 (en)	2012-10-12	2016-08-04	스피로즌 살	Pyrrolobenzodiazepines and conjugates thereof
EP2968585B1 (en)	2013-03-13	2018-07-18	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (en) *	2013-03-28	2019-12-03	삼성전자주식회사	Fusion protein comprising anti-c-Met antibody and VEGF binding fragment
EP2992019B1 (en)	2013-04-30	2019-03-06	Agency For Science, Technology And Research	Mab 2 anti-met antibody
US9567641B2 (en) *	2013-07-03	2017-02-14	Samsung Electronics Co., Ltd.	Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en)	2013-11-15	2017-08-01	Samsung Electronics Co., Ltd.	Method of combination therapy using an anti-C-Met antibody
CA2949045C (en) *	2013-12-20	2022-07-05	Development Center For Biotechnology	Alpha-enolase specific antibodies and methods of uses in cancer therapy
WO2016037644A1 (en)	2014-09-10	2016-03-17	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
CN107613974B (en)	2015-03-16	2021-01-15	塞尔德克斯医疗公司	anti-MET antibodies and methods of use thereof
KR102476846B1 (en) *	2016-02-05	2022-12-12	주식회사 헬릭스미스	Anti-c-MT Antibodies and Uses Thereof
CN109476756B (en)	2016-03-15	2022-05-31	埃泰美德(香港)有限公司	Multi-specificity Fab fusion protein and application thereof
CN114177308B (en)	2016-05-17	2024-07-09	艾伯维生物制药股份有限公司	Anti-cMet antibody drug conjugates and methods of use thereof
US10457726B2 (en)	2016-06-30	2019-10-29	University Of Connecticut	Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
JP2019534882A (en)	2016-10-11	2019-12-05	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	Antibody-drug conjugates with immune-mediated therapeutics
WO2018088933A1 (en) *	2016-11-14	2018-05-17	Limited Liability Company "Panacela Labs"	Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (en)	2016-11-16	2022-11-11	美商再生元醫藥公司	Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
US20180230218A1 (en) *	2017-01-04	2018-08-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
CN109771642B (en) *	2017-11-13	2022-09-20	同济大学苏州研究院	c-MET agonistic antibodies and uses thereof
GB201803892D0 (en) *	2018-03-12	2018-04-25	Ultrahuman Six Ltd	C-met binding agents
JP2021524449A (en)	2018-05-23	2021-09-13	アーデーセーセラピューティクスソシエテアノニム	Molecular adjuvant
KR20250112921A (en) *	2018-08-08	2025-07-24	드래곤플라이 쎄라퓨틱스, 인크.	Proteins binding nkg2d, cd16 and a tumor-associated antigen
US12460000B2 (en)	2018-09-07	2025-11-04	Itabmed (Hk) Limited	Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
CN109541221B (en) *	2018-10-24	2022-03-22	益善生物技术股份有限公司	c-Met specific antibody, composition and kit
KR102353568B1 (en) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability
WO2020132810A1 (en)	2018-12-24	2020-07-02	Generon (Shanghai) Corporation Ltd.	Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN113874392B (en) *	2019-03-28	2025-10-21	丹尼斯科美国公司	Engineered antibodies
CN114340684B (en)	2019-09-16	2025-09-12	瑞泽恩制药公司	Radiolabeled MET-binding protein for immunoPET imaging
KR20230018454A (en)	2020-09-01	2023-02-07	레메젠 코, 리미티드	Anti-c-Met Antibody-Drug Conjugates and Uses Thereof
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
JP2024514506A (en)	2021-04-06	2024-04-02	アッヴィ・バイオセラピューティクス・インコーポレイテッド	Treatment of non-small cell lung cancer with terisotuzumab vedotin
EP4320152A1 (en) *	2021-04-08	2024-02-14	Byondis B.V.	Anti-c-met antibodies and antibody-drug conjugates
AR125473A1 (en) *	2021-04-29	2023-07-19	Abbvie Inc	ANTI-C-MET ANTIBODY AND DRUG CONJUGATES
WO2022078524A2 (en)	2021-11-03	2022-04-21	Hangzhou Dac Biotech Co., Ltd.	Specific conjugation of an antibody
WO2023173109A1 (en)	2022-03-11	2023-09-14	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib
AU2024276234A1 (en)	2023-05-23	2025-12-04	AbbVie Manufacturing Management Unlimited Company	Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4424200A (en)	1979-05-14	1984-01-03	Nuc Med Inc.	Method for radiolabeling proteins with technetium-99m
US4479930A (en)	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JPH05244982A (en)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	Humanized b-b10
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5686292A (en) *	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CA2436326C (en) *	2001-01-09	2012-08-14	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2004072117A2 (en) *	2003-02-13	2004-08-26	Pharmacia Corporation	Antibodies to c-met for the treatment of cancers
HN2004000285A (en)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTIBODIES DIRECTED TO c-MET
JP2008507252A (en) *	2003-12-11	2008-03-13	ジェネンテック・インコーポレーテッド	Methods and compositions for inhibiting C-MET dimerization and activation
AU2005267720B2 (en)	2004-08-05	2012-02-23	Genentech, Inc.	Humanized anti-cmet antagonists
WO2006116260A2 (en) *	2005-04-26	2006-11-02	Medimmune, Inc.	Modulation of antibody effector function by hinge domain engineering
SG196835A1 (en) *	2005-07-18	2014-02-13	Amgen Inc	Human anti-b7rp1 neutralizing antibodies
JP5457671B2 (en) *	2005-07-28	2014-04-02	ノバルティスアーゲー	M-CSF specific monoclonal antibody and use thereof
CN101415730B (en) *	2006-03-30	2013-04-10	诺瓦提斯公司	Compositions and methods of use of c-Met antibodies
EP2014681A1 (en) *	2007-07-12	2009-01-14	Pierre Fabre Medicament	Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody

2009
- 2009-12-01 AR ARP090104624A patent/AR074439A1/en active IP Right Grant
- 2009-12-02 SG SG2013005772A patent/SG187518A1/en unknown
- 2009-12-02 GE GEAP200912279A patent/GEP20135930B/en unknown
- 2009-12-02 WO PCT/EP2009/066201 patent/WO2010069765A1/en not_active Ceased
- 2009-12-02 PL PL16192250T patent/PL3135691T3/en unknown
- 2009-12-02 DK DK16192250.5T patent/DK3135691T3/en active
- 2009-12-02 DK DK09771324.2T patent/DK2370468T3/en active
- 2009-12-02 CN CN200980148150.4A patent/CN102227446B/en active Active
- 2009-12-02 AU AU2009328318A patent/AU2009328318C1/en active Active
- 2009-12-02 ES ES16192250T patent/ES2697098T3/en active Active
- 2009-12-02 PL PL18188726T patent/PL3431502T3/en unknown
- 2009-12-02 MY MYPI2011002426A patent/MY185200A/en unknown
- 2009-12-02 RU RU2015127471A patent/RU2015127471A/en not_active Application Discontinuation
- 2009-12-02 EP EP18188726.6A patent/EP3431502B1/en active Active
- 2009-12-02 MX MX2011005677A patent/MX2011005677A/en active IP Right Grant
- 2009-12-02 RS RS20170671A patent/RS56204B1/en unknown
- 2009-12-02 EP EP20187010.2A patent/EP3757132A1/en active Pending
- 2009-12-02 US US13/132,211 patent/US8741290B2/en active Active
- 2009-12-02 MY MYPI2020006937A patent/MY192567A/en unknown
- 2009-12-02 HU HUE18188726A patent/HUE051288T2/en unknown
- 2009-12-02 SI SI200931680T patent/SI2370468T1/en unknown
- 2009-12-02 CA CA2743433A patent/CA2743433C/en active Active
- 2009-12-02 SG SG2011038817A patent/SG171851A1/en unknown
- 2009-12-02 HR HRP20171011TT patent/HRP20171011T8/en unknown
- 2009-12-02 KR KR1020117013758A patent/KR101838299B1/en active Active
- 2009-12-02 RS RS20181344A patent/RS58018B1/en unknown
- 2009-12-02 BR BR122019023930-4A patent/BR122019023930B1/en active IP Right Grant
- 2009-12-02 PL PL09771324T patent/PL2370468T3/en unknown
- 2009-12-02 PT PT16192250T patent/PT3135691T/en unknown
- 2009-12-02 HU HUE16192250A patent/HUE040553T2/en unknown
- 2009-12-02 EP EP09771324.2A patent/EP2370468B1/en active Active
- 2009-12-02 TW TW098141151A patent/TWI459964B/en active
- 2009-12-02 RU RU2011124751/10A patent/RU2560257C2/en active
- 2009-12-02 GE GEAP200912919A patent/GEP20146207B/en unknown
- 2009-12-02 PT PT97713242T patent/PT2370468T/en unknown
- 2009-12-02 LT LTEP09771324.2T patent/LT2370468T/en unknown
- 2009-12-02 LT LTEP16192250.5T patent/LT3135691T/en unknown
- 2009-12-02 CN CN201310286587.2A patent/CN103351438B/en active Active
- 2009-12-02 HU HUE09771324A patent/HUE035047T2/en unknown
- 2009-12-02 PE PE2011001117A patent/PE20120343A1/en active IP Right Grant
- 2009-12-02 BR BRPI0923231A patent/BRPI0923231B8/en active IP Right Grant
- 2009-12-02 NZ NZ593853A patent/NZ593853A/en unknown
- 2009-12-02 PT PT181887266T patent/PT3431502T/en unknown
- 2009-12-02 ES ES18188726T patent/ES2827277T3/en active Active
- 2009-12-02 EP EP16192250.5A patent/EP3135691B1/en active Active
- 2009-12-02 SI SI200932092T patent/SI3431502T1/en unknown
- 2009-12-02 SI SI200931893T patent/SI3135691T1/en unknown
- 2009-12-02 JP JP2011539008A patent/JP5863458B2/en active Active
- 2009-12-02 TW TW103130374A patent/TWI523866B/en active
- 2009-12-02 ES ES09771324.2T patent/ES2629855T3/en active Active
- 2009-12-05 SA SA112331005A patent/SA112331005B1/en unknown
- 2009-12-05 SA SA109300720A patent/SA109300720B1/en unknown
2011
- 2011-05-03 TN TN2011000216A patent/TN2011000216A1/en unknown
- 2011-05-30 MX MX2015000383A patent/MX341014B/en unknown
- 2011-05-31 IL IL213273A patent/IL213273A0/en active IP Right Grant
- 2011-06-01 CL CL2011001296A patent/CL2011001296A1/en unknown
- 2011-06-10 MA MA33933A patent/MA32892B1/en unknown
- 2011-06-13 CR CR20110324A patent/CR20110324A/en unknown
- 2011-06-13 EC EC2011011127A patent/ECSP11011127A/en unknown
- 2011-06-14 CO CO11073992A patent/CO6382139A2/en active IP Right Grant
- 2011-07-13 ZA ZA2011/05164A patent/ZA201105164B/en unknown
2012
- 2012-09-14 US US13/619,730 patent/US8747850B2/en active Active
- 2012-09-14 US US13/619,910 patent/US8729249B2/en active Active
- 2012-09-14 US US13/619,920 patent/US8765128B2/en active Active
2014
- 2014-01-24 CL CL2014000181A patent/CL2014000181A1/en unknown
- 2014-03-13 IL IL231525A patent/IL231525B/en active IP Right Grant
2015
- 2015-07-03 PH PH12015501515A patent/PH12015501515A1/en unknown
- 2015-12-15 JP JP2015244007A patent/JP6074018B2/en active Active
2016
- 2016-02-04 AU AU2016200725A patent/AU2016200725C1/en active Active
2017
- 2017-01-05 JP JP2017000641A patent/JP6309657B2/en active Active
- 2017-06-09 AU AU2017203929A patent/AU2017203929B2/en active Active
- 2017-07-03 CY CY20171100707T patent/CY1119172T1/en unknown
2018
- 2018-11-09 HR HRP20181868TT patent/HRP20181868T1/en unknown
- 2018-11-09 CY CY181101191T patent/CY1121025T1/en unknown

Also Published As

Publication number	Publication date
DK3135691T3 (en)	2018-11-19
AU2016200725B2 (en)	2017-05-25
IL231525B (en)	2019-07-31
TW201023892A (en)	2010-07-01
HUE035047T2 (en)	2018-05-02
NZ593853A (en)	2013-03-28
AU2017203929B2 (en)	2019-03-28
US8729249B2 (en)	2014-05-20
AU2009328318B2 (en)	2015-11-05
BRPI0923231A2 (en)	2016-01-26
MY192567A (en)	2022-08-29
CY1121025T1 (en)	2019-12-11
KR101838299B1 (en)	2018-03-14
MX341014B (en)	2016-08-03
ES2697098T3 (en)	2019-01-22
ES2629855T3 (en)	2017-08-16
CY1119172T1 (en)	2018-02-14
JP2012510280A (en)	2012-05-10
PH12015501515A1 (en)	2015-12-14
ES2827277T3 (en)	2021-05-20
CL2014000181A1 (en)	2014-07-25
BRPI0923231B8 (en)	2021-05-25
CN102227446B (en)	2015-10-21
HRP20181868T1 (en)	2019-01-11
CO6382139A2 (en)	2012-02-15
EP2370468B1 (en)	2017-04-05
HRP20171011T1 (en)	2017-09-22
WO2010069765A1 (en)	2010-06-24
PL3135691T3 (en)	2019-02-28
DK2370468T3 (en)	2017-06-19
CR20110324A (en)	2011-07-28
RU2015127471A (en)	2018-12-21
IL231525A0 (en)	2014-04-30
HK1162536A1 (en)	2012-08-31
PL3431502T3 (en)	2020-12-28
CA2743433A1 (en)	2010-06-24
JP6074018B2 (en)	2017-02-01
CA2743433C (en)	2019-06-11
PT3135691T (en)	2018-11-27
JP2017099392A (en)	2017-06-08
JP2016117721A (en)	2016-06-30
CN103351438B (en)	2016-04-20
SI3431502T1 (en)	2021-01-29
MA32892B1 (en)	2011-12-01
SA109300720B1 (en)	2013-05-25
SI2370468T1 (en)	2017-08-31
US20130109841A1 (en)	2013-05-02
MY185200A (en)	2021-04-30
EP3135691A1 (en)	2017-03-01
PL2370468T3 (en)	2017-09-29
GEP20135930B (en)	2013-10-10
SG187518A1 (en)	2013-02-28
RS58018B1 (en)	2019-02-28
EP3431502A1 (en)	2019-01-23
JP5863458B2 (en)	2016-02-16
LT2370468T (en)	2017-07-10
AU2016200725C1 (en)	2017-10-19
CN103351438A (en)	2013-10-16
RS56204B1 (en)	2017-11-30
BR122019023930B1 (en)	2021-05-04
EP3135691B1 (en)	2018-08-15
ZA201105164B (en)	2012-03-28
HRP20171011T8 (en)	2019-01-25
IL213273A0 (en)	2011-07-31
TWI523866B (en)	2016-03-01
US8747850B2 (en)	2014-06-10
JP6309657B2 (en)	2018-04-11
HUE051288T2 (en)	2021-03-01
US20130109840A1 (en)	2013-05-02
SA112331005B1 (en)	2015-09-13
US8741290B2 (en)	2014-06-03
TWI459964B (en)	2014-11-11
TW201446805A (en)	2014-12-16
US8765128B2 (en)	2014-07-01
GEP20146207B (en)	2014-12-10
BRPI0923231B1 (en)	2020-04-28
AU2009328318A1 (en)	2011-07-28
EP2370468A1 (en)	2011-10-05
PT3431502T (en)	2020-10-29
PT2370468T (en)	2017-07-13
RU2560257C2 (en)	2015-08-20
ECSP11011127A (en)	2011-07-29
AU2016200725A1 (en)	2016-02-25
AU2017203929A1 (en)	2017-07-06
EP3431502B1 (en)	2020-07-22
RU2011124751A (en)	2013-01-10
US20110239316A1 (en)	2011-09-29
EP3757132A1 (en)	2020-12-30
US20130109844A1 (en)	2013-05-02
SG171851A1 (en)	2011-07-28
HK1190414A1 (en)	2014-07-04
KR20110097839A (en)	2011-08-31
HUE040553T2 (en)	2019-03-28
LT3135691T (en)	2018-11-12
TN2011000216A1 (en)	2012-12-17
AU2009328318C1 (en)	2017-11-02
AR074439A1 (en)	2011-01-19
CN102227446A (en)	2011-10-26
CL2011001296A1 (en)	2011-08-26
PE20120343A1 (en)	2012-04-16
MX2011005677A (en)	2011-06-30

Publication	Publication Date	Title
HRP20181868T1 (en)	2019-01-11	Anti-cmet antibody
IL276622A (en)	2020-09-30	Antibody formulation
ZA201102119B (en)	2011-12-28	Improved antibody libraies
IL209142A0 (en)	2011-01-31	Anti-flt3 antibodies
GB0821100D0 (en)	2008-12-24	Antibodies
EP2077859A4 (en)	2010-11-24	Antibody formulation
EP2138576A4 (en)	2011-02-23	Anti-claudin-4 antibody
SI2146745T1 (en)	2015-10-30	penta-specific antibody
IL211190A0 (en)	2011-04-28	Novel antibody formulation
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
GB0817622D0 (en)	2008-11-05	Antibody
GB0817621D0 (en)	2008-11-05	Antibody
GB0823562D0 (en)	2009-01-28	Antibodies
GB0806230D0 (en)	2008-05-14	Antibodies
GB0819113D0 (en)	2008-11-26	An antibody